Enochian Biosciences Inc (ENOB) Director Rene Sindlev Purchases 20,000 Shares

Share on StockTwits

Enochian Biosciences Inc (OTCMKTS:ENOB) Director Rene Sindlev acquired 20,000 shares of the stock in a transaction dated Tuesday, May 21st. The stock was acquired at an average price of $5.75 per share, with a total value of $115,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of ENOB opened at $6.45 on Friday. Enochian Biosciences Inc has a fifty-two week low of $3.32 and a fifty-two week high of $9.50.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlueCrest Capital Management Ltd bought a new stake in shares of Enochian Biosciences in the 1st quarter worth approximately $129,000. Morgan Stanley bought a new stake in shares of Enochian Biosciences in the 1st quarter worth approximately $26,000. ExodusPoint Capital Management LP bought a new stake in shares of Enochian Biosciences in the 1st quarter worth approximately $227,000. Marshall Wace LLP bought a new stake in shares of Enochian Biosciences in the 1st quarter worth approximately $60,000. Finally, Citigroup Inc. bought a new stake in shares of Enochian Biosciences in the 1st quarter worth approximately $108,000.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4353058/enochian-biosciences-inc-enob-director-rene-sindlev-purchases-20000-shares.html.

Enochian Biosciences Company Profile

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

Featured Story: Understanding Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report